Compare BNC & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BNC | ACRS |
|---|---|---|
| Founded | N/A | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 287.3M | 314.2M |
| IPO Year | N/A | 2015 |
| Metric | BNC | ACRS |
|---|---|---|
| Price | $6.40 | $3.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $9.75 |
| AVG Volume (30 Days) | 616.0K | ★ 1.2M |
| Earning Date | 12-15-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 18.98 | N/A |
| Revenue | $3,721,498.00 | ★ $15,742,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.34 | ★ N/A |
| Revenue Growth | ★ 41.12 | N/A |
| 52 Week Low | $4.65 | $1.05 |
| 52 Week High | $82.88 | $3.48 |
| Indicator | BNC | ACRS |
|---|---|---|
| Relative Strength Index (RSI) | 46.73 | 53.07 |
| Support Level | $6.02 | $2.88 |
| Resistance Level | $6.70 | $3.09 |
| Average True Range (ATR) | 0.45 | 0.17 |
| MACD | -0.00 | -0.05 |
| Stochastic Oscillator | 24.37 | 32.37 |
CEA Industries Inc through its subsidiary is focused on selling environmental control and other technologies and services to the Controlled Environment Agriculture ("CEA") industry. The company provides integrated mechanical, electrical, and plumbing ("MEP") engineering design, proprietary and curated environmental control equipment, and automation offerings that serve the CEA industry. The Company has one operating segment that is dedicated to the manufacture and sale of its products.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.